Abstract
A disease is a multifactorial dysfunction of system that affects the structure and function in an organism. In the same way, neurological disorders are associated with multiple factors like gene overexpression, repression, complete knockout, protein misfolding, metabolic dysfunction, microbial infection, or dysbiosis of microbiome. It is an established fact that several neurodegenerative, neurobehavioural, mental, and metabolic disorders including Alzheimer’s, Parkinson’s, Huntington’s, schizophrenia, multiple sclerosis, depression, and obesity have been allied to microbiota. Microbiome solely might not be the cause of any disease, but its contribution is significant. The molecular interactions between gut microbiome and nervous system are complex and bidirectional; any alterations in the gut–brain axis might leads to gastrointestinal and neurological disorders. It is easy to manipulate gut microbiome rather than the brain for better therapies, so this chapter deals with microbiome association in development of neurological disorders.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Abuelezz NZ, Nasr FE, AbdulKader MA, Bassiouny AR, Zaky A (2021) MicroRNAs as potential orchestrators of Alzheimer’s disease-related pathologies: insights on current status and future possibilities. Front Aging Neurosci 13:743573. https://doi.org/10.3389/fnagi.2021.743573
Akbari E, Asemi Z, Daneshvar Kakhaki R, Bahmani F, Kouchaki E, Tamtaji OR, Hamidi GA, Salami M (2016) Effect of probiotic supplementation on cognitive function and metabolic status in Alzheimer’s disease: a randomized, double-blind and controlled trial. Front Aging Neurosci 10(8):256. https://doi.org/10.3389/fnagi.2016.00256
Akhondzadeh S (2019) Microbiome and schizophrenia. Avicenna J Med Biotechnol 11(4):269. PMID: 31908733; PMCID: PMC6925402
Alonso R, Pisa D, Carrasco L (2019) Brain microbiota in Huntington’s disease patients. Front Microbiol 10:2622. https://doi.org/10.3389/fmicb.2019.02622
Amini ME, Shomali N, Bakhshi A, Rezaei S, Hemmatzadeh M, Hosseinzadeh R, Eslami S, Babaie F, Aslani S, Torkamandi S, Mohammadi H (2020) Gut microbiome and multiple sclerosis: new insights and perspective. Int Immunopharmacol 88:107024. https://doi.org/10.1016/j.intimp.2020.107024
Beitz JM (2014) Parkinson’s disease: a review. Front Biosci (Schol Ed) 6(1):65–74. https://doi.org/10.2741/s415
Blacher E, Bashiardes S, Shapiro H, Rothschild D, Mor U, Dori-Bachash M et al (2019) Potential roles of gut microbiome and metabolites in modulating ALS in mice. Nature 572:474–480. https://doi.org/10.1038/s41586-019-1443-5
Borsook D (2012) Neurological diseases and pain. Brain 135(pt 2):320–344. https://doi.org/10.1093/brain/awr271
Burberry A, Wells MF, Limone F, Couto A, Smith KS, Keaney J et al (2020) C9orf72 suppresses systemic and neural inflammation induced by gut bacteria. Nature 582:89–94. https://doi.org/10.1038/s41586-020-2288-7
Cantoni C, Qingqi L, Dorsett Y, Ghezzi L, Liu Z, Pan Y, Chen K, Han Y, Li Z, Xiao H, Gormley M, Liu Y, Bokoliya S, Panier H, Suther C, Evans E, Deng L, Locca A, Mikesell R, Zhou Y (2022) Alterations of host-gut microbiome interactions in multiple sclerosis. EBioMedicine 76:103798. https://doi.org/10.1016/j.ebiom.2021.103798
Carabotti M, Scirocco A, Maselli MA, Severi C (2015) The gut-brain axis: interactions between enteric microbiota, central and enteric nervous systems. Ann Gastroenterol 28(2):203–209. PMID: 25830558; PMCID: PMC4367209
Carding S, Verbeke K, Vipond DT, Corfe BM, Owen LJ (2015) Dysbiosis of the gut microbiota in disease. Microb Ecol Health Dis 26:26191. https://doi.org/10.3402/mehd.v26.26191
Cerdó T, Diéguez E, Campoy C (2020) Impact of gut microbiota on neurogenesis and neurological diseases during infancy. Curr Opin Pharmacol 50:33. https://doi.org/10.1016/j.coph.2019.11.006
Cersosimo MG, Benarroch EE (2012) Pathological correlates of gastrointestinal dysfunction in Parkinson’s disease. Neurobiol Dis 46:559–564. https://doi.org/10.1016/j.nbd.2011.10.014
Checkoway H, Lundin JI, Kelada SN (2011) Neurodegenerative diseases. IARC Sci Publ 163:407–419. PMID: 22997874
Chen J, Chia N, Kalari KR, Yao JZ, Novotna M, Paz Soldan MM, Luckey DH, Marietta EV, Jeraldo PR, Chen X, Weinshenker BG, Rodriguez M, Kantarci OH, Nelson H, Murray JA, Mangalam AK (2016) Multiple sclerosis patients have a distinct gut microbiota compared to healthy controls. Sci Rep 6:28484. https://doi.org/10.1038/srep28484
Cheng LH, Liu YW, Wu CC, Wang S, Tsai YC (2019) Psychobiotics in mental health, neurodegenerative and neurodevelopmental disorders. J Food Drug Anal 27(3):632–648. https://doi.org/10.1016/j.jfda.2019.01.002
Chin-Chan M, Navarro-Yepes J, Quintanilla-Vega B (2015) Environmental pollutants as risk factors for neurodegenerative disorders: Alzheimer and Parkinson diseases. Front Cell Neurosci 9:124. https://doi.org/10.3389/fncel.2015.00124
Cogliati S, Clementi V, Francisco M, Crespo C, Argañaraz F, Grau R (2020) Bacillus subtilis delays neurodegeneration and behavioral impairment in the Alzheimer’s disease model Caenorhabditis elegans. J Alzheimers Dis 73(3):1035–1052. https://doi.org/10.3233/JAD-190837
Delcourt N, Claudepierre T, Maignien T, Arnich N, Mattei C (2017) Cellular and molecular aspects of the β-N-methylamino-l-alanine (BMAA) mode of action within the neurodegenerative pathway: facts and controversy. Toxins (Basel) 10(1):6. https://doi.org/10.3390/toxins10010006
Dendrou CA, Fugger L, Friese MA (2015) Immunopathology of multiple sclerosis. Nat Rev Immunol 15(9):545–558. https://doi.org/10.1038/nri3871
DeTure MA, Dickson DW (2019) The neuropathological diagnosis of Alzheimer’s disease. Mol Neurodegener 14:32. https://doi.org/10.1186/s13024-019-0333-5
Dominy SS, Casey L, Florian E, Malgorzata B, Agata M, Andrei K, Mai N, Ursula H, Debasish R, Griffin C, Leslie HJ, Shirin A-K, Samer K, Alexander L, Mark RI, Barbara P, Piotr M, Annelie H, Karina A, Hatice H, Glenn WD, Eri RC, Faull RLM, Curtis Maurice A, Mike D, Jan P (2019) Porphyromonas gingivalis in Alzheimer’s disease brains: evidence for disease causation and treatment with small-molecule inhibitors. Sci Adv 5:eaau3333. https://doi.org/10.1126/sciadv.aau3333
Du G, Dong W, Yang Q, Yu X, Ma J, Gu W, Huang Y (2021) Altered gut microbiota related to inflammatory responses in patients with Huntington’s disease. Front Immunol 11:603594. https://doi.org/10.3389/fimmu.2020.603594
Duncan ID, Watters JJ (2019) Remyelination and the gut−brain axis. Proc Natl Acad Sci U S A 116:24922. https://doi.org/10.1073/pnas.1918897116
Fan Y, Zhang J (2019) Dietary modulation of intestinal microbiota: future opportunities in experimental autoimmune encephalomyelitis and multiple sclerosis. Front Microbiol 10:740. https://doi.org/10.3389/fmicb.2019.00740
Filippi M, Bar-Or A, Piehl F et al (2018) Multiple sclerosis. Nat Rev Dis Primers 4:43. https://doi.org/10.1038/s41572-018-0041-4
Gao F, Guod R, Ma Q, Li Y, Wang W, Fan Y, Ju Y, Zhao B, Gao Y, Qian L, Yang Z, He X, Jin X, Liu Y, Peng Y, Chen C, Chen Y, Gao C et al (2022) Stressful events induce long-term gut microbiota dysbiosis and associated post-traumatic stress symptoms in healthcare workers fighting against COVID-19. J Affect Disord 303(15):187–195. https://doi.org/10.1016/j.jad.2022.02.024
Geng S, Yang L, Cheng F, Zhang Z, Li J, Liu W, Li Y, Chen Y, Bao Y, Chen L, Fei Z, Li X, Hou J, Lin Y, Liu Z, Zhang S, Wang H, Zhang Q, Wang H, Wang X, Zhang J (2020) Gut microbiota are associated with psychological stress-induced defections in intestinal and blood–brain barriers. Front Microbiol 10:3067. https://doi.org/10.3389/fmicb.2019.03067
Ghosh R, Tabrizi SJ (2018) Clinical features of Huntington’s disease. Adv Exp Med Biol 1049:1–28. https://doi.org/10.1007/978-3-319-71779-1_1
Gómez-Benito M, Granado N, García-Sanz P, Michel A, Dumoulin M, Moratalla R (2020) Modeling Parkinson’s disease with the alpha-synuclein protein. Front Pharmacol 11:356. https://doi.org/10.3389/fphar.2020.00356
Haque RU, Levey AI (2019) Alzheimer’s disease: a clinical perspective and future nonhuman primate research opportunities. Proc Natl Acad Sci U S A 116(52):26224–26229. https://doi.org/10.1073/pnas.1912954116
Haran JP, Bhattarai SK, Foley SE, Dutta P, Ward DV, Bucci V, McCormick BA (2019) Alzheimer’s disease microbiome is associated with dysregulation of the anti-inflammatory P-glycoprotein pathway. MBio 10(3):e00632–e00619. https://doi.org/10.1128/mBio.00632-19
Hardiman O, Al-Chalabi A, Chio A, Corr EM, Logroscino G, Robberecht W, Shaw PJ, Simmons Z, van den Berg LH (2017) Amyotrophic lateral sclerosis. Nat Rev Dis Primers 3:17071. https://doi.org/10.1038/nrdp.2017.71
He Y, Li B, Sun D, Chen S (2020) Gut microbiota: implications in Alzheimer’s disease. J Clin Med 9(7):2042. https://doi.org/10.3390/jcm9072042
Hu X, Wang T, Jin F (2016) Alzheimer’s disease and gut microbiota. Sci China Life Sci 59(10):1006–1023. https://doi.org/10.1007/s11427-016-5083-9
Huang HJ, Chen JL, Liao JF, Chen YH, Chieu MW, Ke YY, Hsu CC, Tsai YC, Hsieh-Li HM (2021) Lactobacillus plantarum PS128 prevents cognitive dysfunction in Alzheimer’s disease mice by modulating propionic acid levels, glycogen synthase kinase 3 beta activity, and gliosis. BMC Complement Med Ther 21(1):259. https://doi.org/10.1186/s12906-021-03426-8
Hulisz D (2018) Amyotrophic lateral sclerosis: disease state overview. Am J Manag Care 24:S320–S326. PMID: 30207670
Karakan T, Ozkul C, Küpeli Akkol E, Bilici S, Sobarzo-Sánchez E, Capasso R (2021) Gut-brain-microbiota axis: antibiotics and functional gastrointestinal disorders. Nutrients 13(2):389. https://doi.org/10.3390/nu13020389
Kelly JR, Minuto C, Cryan JF, Clarke G, Dinan TG (2021) The role of the gut microbiome in the development of schizophrenia. Schizophr Res 234:4–23. https://doi.org/10.1016/j.schres.2020.02.010
Kong G, Cao KL, Judd LM, Li S, Renoir T, Hannan AJ (2020) Microbiome profiling reveals gut dysbiosis in a transgenic mouse model of Huntington’s disease. Neurobiol Dis 135:104268. https://doi.org/10.1016/j.nbd.2018.09.001
Kouchaki E, Tamtaji OR, Salami M, Bahmani F, Daneshvar Kakhaki R, Akbari E, Tajabadi-Ebrahimi M, Jafari P, Asemi Z (2017) Clinical and metabolic response to probiotic supplementation in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled trial. Clin Nutr 36(5):1245–1249. https://doi.org/10.1016/j.clnu.2016.08.015
Kumar P, Lee JH, Lee J (2021) Diverse roles of microbial indole compounds in eukaryotic systems. Biol Rev Camb Philos Soc 96(6):2522–2545. https://doi.org/10.1111/brv.12765
Lakra P, Aditi K, Agrawal N (2019) Peripheral expression of mutant huntingtin is a critical determinant of weight loss and metabolic disturbances in Huntington’s disease. Sci Rep 9:10127. https://doi.org/10.1038/s41598-019-46470-8
Liao JF, Cheng YF, You ST, Kuo WC, Huang CW, Chiou JJ, Hsu CC, Hsieh-Li HM, Wang S, Tsai YC (2020) Lactobacillus plantarum PS128 alleviates neurodegenerative progression in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced mouse models of Parkinson’s disease. Brain Behav Immun 90:26–46. https://doi.org/10.1016/j.bbi.2020.07.036
Lotankar S, Prabhavalkar KS, Bhatt LK (2017) Biomarkers for Parkinson’s disease: recent advancement. Neurosci Bull 33(5):585–597. https://doi.org/10.1007/s12264-017-0183-5
Lu CS, Chang HC, Weng YH, Chen CC, Kuo YS, Tsai YC (2021) The add-on effect of Lactobacillus plantarum PS128 in patients with Parkinson’s disease: a pilot study. Front Nutr 8:650053. https://doi.org/10.3389/fnut.2021.650053
Macleod S, Appleton RE (2007) Neurological disorders presenting mainly in adolescence. Arch Dis Child 92(2):170–175. https://doi.org/10.1136/adc.2005.088070
Madison A, Kiecolt-Glaser JK (2019) Stress, depression, diet, and the gut microbiota: human-bacteria interactions at the core of psychoneuroimmunology and nutrition. Curr Opin Behav Sci 28:105–110. https://doi.org/10.1016/j.cobeha.2019.01.011
Mancuso C, Santangelo R (2018) Alzheimer’s disease and gut microbiota modifications: the long way between preclinical studies and clinical evidence. Pharmacol Res 129:329–336. https://doi.org/10.1016/j.phrs.2017.12.009
Martinez JE, Kahana DD, Ghuman S, Wilson HP, Wilson J, Kim SCJ, Lagishetty V, Jacobs JP, Sinha-Hikim AP, Friedman TC (2021) Unhealthy lifestyle and gut dysbiosis: a better understanding of the effects of poor diet and nicotine on the intestinal microbiome. Front Endocrinol (Lausanne) 12:667066. https://doi.org/10.3389/fendo.2021.667066
Minter M, Zhang C, Leone V et al (2016) Antibiotic-induced perturbations in gut microbial diversity influences neuro-inflammation and amyloidosis in a murine model of Alzheimer’s disease. Sci Rep 6:30028. https://doi.org/10.1038/srep30028
Mohankumar A, Kalaiselvi D, Thiruppathi G, Patteswari D, Tawata S, Sundararaj P (2022) Psychobiotics in health, longevity, and neurological disorders. In: Rajagopal S, Ramachandran S, Sundararaman G, Gadde Venkata S (eds) Role of nutrients in neurological disorders. Nutritional neurosciences. Springer, Singapore. https://doi.org/10.1007/978-981-16-8158-5_2
Morera-Fumero AL, Abreu-Gonzalez P (2013) Role of melatonin in schizophrenia. Int J Mol Sci 14(5):9037–9050. https://doi.org/10.3390/ijms14059037
Murphy MP, LeVine H III (2010) Alzheimer’s disease and the amyloid-beta peptide. J Alzheimers Dis 19(1):311–323. https://doi.org/10.3233/JAD-2010-1221
Nguyen HP, Van Broeckhoven C, van der Zee J (2018) ALS genes in the genomic era and their implications for FTD. Trends Genet 34(6):404–423. https://doi.org/10.1016/j.tig.2018.03.001
Nicholson K, Bjornevik K, Abu-Ali G, Chan J, Cortese M, Dedi B, Jeon M, Xavier R, Huttenhower C, Ascherio A, Berry JD (2021) The human gut microbiota in people with amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener 22(3-4):186–194. https://doi.org/10.1080/21678421.2020.1828475
Obrenovich M, Jaworski H, Tadimalla T, Mistry A, Sykes L, Perry G, Bonomo RA (2020) The role of the microbiota-gut-brain axis and antibiotics in ALS and neurodegenerative diseases. Microorganisms 8(5):784. https://doi.org/10.3390/microorganisms8050784
Okubo R, Koga M, Katsumata N et al (2019) Effect of Bifidobacterium breve A-1 on anxiety and depressive symptoms in schizophrenia: a proof-of-concept study. J Affect Disord 245:377–385. https://doi.org/10.1016/j.jad.2018.11.011
Pandey M, Rajamma U (2018) Huntington’s disease: the coming of age. J Genet 97(3):649–664. https://doi.org/10.1007/s12041-018-0957-1
Parker A, Fonseca S, Carding SR (2020) Gut microbes and metabolites as modulators of blood-brain barrier integrity and brain health. Gut Microbes 11(2):135–157. https://doi.org/10.1080/19490976.2019.1638722
Peterson CT (2020) Dysfunction of the microbiota-gut-brain axis in neurodegenerative disease: the promise of therapeutic modulation with prebiotics, medicinal herbs, probiotics, and synbiotics. J Evid-Based Integr Med 25:2515690X20957225. https://doi.org/10.1177/2515690X20957225
Proctor EA, Mowrey DD, Dokholyan NV (2019) β-Methylamino-L-alanine substitution of serine in SOD1 suggests a direct role in ALS etiology. PLoS Comput Biol 15(7):e1007225. https://doi.org/10.1371/journal.pcbi.1007225
Roberts AL, Johnson NJ, Cudkowicz ME et al (2016) Job-related formaldehyde exposure and ALS mortality in the USA. J Neurol Neurosurg Psychiatry 87:786–788. https://doi.org/10.1136/jnnp-2015-310750
Romano S, Savva GM, Bedarf JR et al (2021) Meta-analysis of the Parkinson’s disease gut microbiome suggests alterations linked to intestinal inflammation. NPJ Parkinsons Dis 7:27. https://doi.org/10.1038/s41531-021-00156-z
Sampson TR, Debelius JW, Thron T, Janssen S, Shastri GG, Ilhan ZE, Challis C, Schretter CE, Rocha S, Gradinaru V, Chesselet MF, Keshavarzian A, Shannon KM, Krajmalnik-Brown R, Wittung-Stafshede P, Knight R, Mazmanian SK (2016) Gut microbiota regulate motor deficits and neuroinflammation in a model of Parkinson’s disease. Cell 167(6):1469–1480.e12. https://doi.org/10.1016/j.cell.2016.11.018
Sarkar A, Lehto SM, Harty S, Dinan TG, Cryan JF, Burnet P (2016) Psychobiotics and the manipulation of bacteria-gut-brain signals. Trends Neurosci 39(11):763–781. https://doi.org/10.1016/j.tins.2016.09.002
Schwarz E, Maukonen J, Hyytiäinen T et al (2018) Analysis of microbiota in first episode psychosis identifies preliminary associations with symptom severity and treatment response. Schizophr Res 192:398–403. https://doi.org/10.1016/j.schres.2017.04.017
Seals RM, Kioumourtzoglou MA, Gredal O, Hansen J, Weisskopf MG (2017) Occupational formaldehyde and amyotrophic lateral sclerosis. Eur J Epidemiol 32(10):893–899. https://doi.org/10.1007/s10654-017-0249-8
Siuly S, Zhang Y (2016) Medical big data: neurological diseases diagnosis through medical data analysis. Data Sci Eng 1:54–64. https://doi.org/10.1007/s41019-016-0011-3
Suganya K, Koo BS (2020) Gut–brain axis: role of gut microbiota on neurological disorders and how probiotics/prebiotics beneficially modulate microbial and immune pathways to improve brain functions. Int J Mol Sci 21(20):7551. https://doi.org/10.3390/ijms21207551
Sun J, Zhan Y, Mariosa LH, Almqvist C, Ingre C et al (2019) Antibiotics use and risk of amyotrophic lateral sclerosis in Sweden. Eur J Neurol 26:1355–1361. https://doi.org/10.1111/ene.13986
Taan M, Al Ahmad F, Ercksousi MK, Hamza G (2021) Risk factors associated with multiple sclerosis: a case-control study in Damascus, Syria. Mult Scler Int 2021:8147451. https://doi.org/10.1155/2021/8147451
Verma A (2021) Clinical manifestation and management of amyotrophic lateral sclerosis. In: Araki T (ed) Chapter 1. Amyotrophic Lateral Sclerosis. Exon Publications, Brisbane. https://doi.org/10.36255/exonpublications.amyotrophiclateralsclerosis.management.2021
Walker FO (2007) Huntington’s disease. Lancet 369(9557):218–228. https://doi.org/10.1016/S0140-6736(07)60111-1
Wang P, Tu K, Cao P, Yang Y, Zhang H, Qiu XT, Zhang MM, Wu XJ, Yang H, Chen T (2021) Antibiotics-induced intestinal dysbacteriosis caused behavioral alternations and neuronal activation in different brain regions in mice. Mol Brain 14(1):49. https://doi.org/10.1186/s13041-021-00759-w
Wasser CI, Mercieca EC, KongG HAJ, McKeown SJ, Glikmann-Johnston Y, Stout JC (2020) Gut dysbiosis in Huntington’s disease: associations among gut microbiota, cognitive performance, and clinical outcomes. Brain Commun 2(2):fcaa110. https://doi.org/10.1093/braincomms/fcaa110
Waubant E, Lucas R, Mowry E, Graves J, Olsson T, Alfredsson L, Langer-Gould A (2019) Environmental and genetic risk factors for MS: an integrated review. Ann Clin Transl Neurol 6(9):1905–1922. https://doi.org/10.1002/acn3.50862
Weiss GA, Hennet T (2017) Mechanisms and consequences of intestinal dysbiosis. Cell Mol Life Sci 74(16):2959–2977. https://doi.org/10.1007/s00018-017-2509-x
Wu S, Liu X, Jiang R, Yan X, Ling Z (2021) Roles and mechanisms of gut microbiota in patients with Alzheimer’s disease. Front Aging Neurosci 13:650047. https://doi.org/10.3389/fnagi.2021.650047
Zeng Q, Shen J, Chen K et al (2020) The alteration of gut microbiome and metabolism in amyotrophic lateral sclerosis patients. Sci Rep 10:12998. https://doi.org/10.1038/s41598-020-69845-8
Zhang S, Cooper-Knock J, Weimer AK, Shi M, Moll T, JNG M, Harvey C, Nezhad HG, Franklin J, CDS S, Ning K, Wang C, Li J, Dilliott AA, Farhan S, Elhaik E, Pasniceanu I, Livesey MR, Eitan C, Hornstein E, Kenna KP, Project MinE ALS Sequencing Consortium, Veldink JH, Ferraiuolo L, Shaw PJ, Snyder MP (2022) Genome-wide identification of the genetic basis of amyotrophic lateral sclerosis. Neuron 110(6):992–1008.e11. https://doi.org/10.1016/j.neuron.2021.12.019
Zhu F, Ju Y, Wang W et al (2020) Metagenome-wide association of gut microbiome features for schizophrenia. Nat Commun 11:1612. https://doi.org/10.1038/s41467-020-15457-9
Zhu G, Zhao J, Zhang H, Chen W, Wang G (2021) Administration of Bifidobacterium breve improves the brain function of Aβ1-42-treated mice via the modulation of the gut microbiome. Nutrients 13(5):1602. https://doi.org/10.3390/nu13051602
Zielonka D, Piotrowska I, Marcinkowski JT, Mielcarek M (2014) Skeletal muscle pathology in Huntington’s disease. Front Physiol 5:380. https://doi.org/10.3389/fphys.2014.00380
Acknowledgement
The author is thankful to Vice Chancellor and Registrar, Pondicherry University, Pondicherry, India for providing the facilities for ongoing research work and to UGC, Govt. of India for providing financial assistance in the form of DSK postdoctoral fellowship BL/19-20/0302.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2023 The Author(s), under exclusive license to Springer Nature Singapore Pte Ltd.
About this chapter
Cite this chapter
Pamanji, R., Selvin, J. (2023). Human Microbiome and the Neurological Disorders. In: Kothari, V., Kumar, P., Ray, S. (eds) Probiotics, Prebiotics, Synbiotics, and Postbiotics. Springer, Singapore. https://doi.org/10.1007/978-981-99-1463-0_8
Download citation
DOI: https://doi.org/10.1007/978-981-99-1463-0_8
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-99-1462-3
Online ISBN: 978-981-99-1463-0
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)